A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Trial Details

NCT ID

NCT07172802

Phase

PHASE1 / PHASE2

Sponsor

GI Innovation, Inc.

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

• GI-108

Locations (sample)

• Seoul, South Korea|37.566,126.9784
• Seoul, South Korea|37.566,126.9784
• Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

• Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatoryguidelines) at the time of screening.
• Has adequate organ and marrow function as defined in protocol.
• Measurable disease as per RECIST v1.1.
• ECOG performance status 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.